|1.||Pozzi, P: 3 articles (12/2000 - 02/2000)|
|2.||Bajetta, E: 3 articles (12/2000 - 02/2000)|
|3.||Zilembo, N: 3 articles (12/2000 - 02/2000)|
|4.||Ruggeri, Enzo Maria: 2 articles (10/2005 - 07/2003)|
|5.||Carlini, Paolo: 2 articles (10/2005 - 07/2003)|
|6.||Papaldo, Paola: 2 articles (10/2005 - 07/2003)|
|7.||Ferretti, Gianluigi: 2 articles (10/2005 - 07/2003)|
|8.||Cognetti, Francesco: 2 articles (10/2005 - 07/2003)|
|9.||Fabi, Alessandra: 2 articles (10/2005 - 07/2003)|
|10.||Di Cosimo, Serena: 2 articles (10/2005 - 07/2003)|
|1.||Breast Neoplasms (Breast Cancer)
08/01/2000 - "Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability."
04/01/2000 - "Among the steroid substrate analogs, formestane and examestane have been shown to be effective in breast cancer patients with advanced disease. "
01/01/1994 - "Among the steroid substrate analogues, 4-hydroxyandrostenedione (4-OHA) has been shown to be effective in breast cancer patients with advanced disease and was recently approved for treatment in the United Kingdom. "
12/01/1993 - "Among the steroid substrate analogs, 4-hydroxyandrostenedione has been shown to be effective in breast cancer patients with advanced disease and was recently approved for treatment in the United Kingdom. "
01/01/1992 - "We conclude that 4-hydroxyandrostenedione at 250 mg every 2 weeks is a safe and effective form of treatment for postmenopausal patients with metastatic breast cancer."
04/01/2007 - "Compared to a tumor area of 1400 mm2 after 21 days of unopposed tumor growth, formestane treatment, irrespective of concomitant black cohosh application, significantly reduced neoplastic growth by 50%. "
11/01/1995 - "The patients were considered evaluable for tumor response after four doses of formestane. "
12/31/1994 - "Patients were evaluable for tumor response after 4 doses of formestane. "
12/01/1994 - "In contrast, neither dose of 4-hydroxyandrostenedione had any effect on tumor incidence and only the higher dose slightly decreased tumor multiplicity."
07/15/1991 - "Other experiments were performed to evaluate the effects of 4-OHA on tumor-bearing male mice in vivo. "
04/01/1993 - "To assess the efficacy of the aromatase inhibitor 4-hydroxyandrostenedione (4-OHA) as first-line treatment in patients who were either resistant to or had relapsed after adjuvant therapy, 50 eligible patients received intramuscular 4-OHA either 250 mg or 500 mg fortnightly until disease progression or severe adverse events. "
06/01/1999 - "The Swiss Group for Clinical Cancer Research (SAKK) compared efficacy and toxicity of formestane (250 mg intramuscularly (i.m.) every 2 weeks) versus megestrol acetate (MGA; 160 mg orally daily) as second-line treatment in postmenopausal patients with advanced breast cancer and disease progression while on tamoxifen treatment in a randomised trial (Thürlimann B, Castiglione M, Hsu Schmitz SF, et al. Eur J Cancer 1997, 33, 1017-1024). "
04/01/2007 - "Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma."
05/01/1999 - "4 of 9 patients who progressed on formestane also stabilised on anastrozole, of whom 3 had oestrogen receptor positive breast carcinomas. "
08/01/1982 - "Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model."
07/15/1995 - "The effects of aromatase inhibitors 4-hydroxyandrostenedione (4-OHA), CGS 16949A, and CGS 20267, and of the antiestrogen tamoxifen (TAM), were studied on the growth of human breast carcinoma in a nude mouse model. "
03/01/1998 - "To elucidate one possible mechanism of tamoxifen resistance, we treated ovariectomized tumor-bearing mice injected with fibroblast growth factor (FGF)-transfected MCF-7 breast carcinoma cells with the steroidal antiestrogen ICI 182,780 or one of two aromatase inhibitors, 4-OHA or letrozole. "
|5.||Neoplasm Metastasis (Metastasis)
01/01/1993 - "Soft tissue metastases generally show the best response to formestane treatment while visceral metastases (in particular liver) show a poor response. "
01/01/1997 - "In this study we have evaluated osteoblastic and osteoclastic markers in 18 patients with bone metastases from breast cancer at diagnosis and for 1 year of follow-up during treatment with the aromatase inhibitor formestane. "
01/01/1997 - "Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane."
|2.||Drug Therapy (Chemotherapy)